MaxCyte, Inc. provided earnings guidance for the year ended December 31, 2017. For the period, the company expects to report revenues of approximately $14.0 million, an increase of approximately 14% over 2016 revenues of $12.3 million. EBITDA for the period is expected to be in line with market expectations.